Magnitude Biosciences secures UK government Future Fund to expand its workforce.
Durham, UK – August 2020
Research into new medicines is needed more than ever, but research labs across the world are slowing down because of COVID-19 restrictions. Many companies and universities are turning increasingly to contract research organisations (CROs) to outsource their research. To meet this need, Magnitude Biosciences, a specialist CRO in CountyDurham, has secured funding from the government Coronavirus Future Fund.
The Coronavirus Future Fund invests in innovative UK companies to
boost their activity during the pandemic. Current investors in Magnitude Biosciences, Saker Capital and North East Innovation Fund run by Northstar Ventures Capital, have matched the government funds. In total, £250,000 will be used to grow the company’s workforce and facilities at NETPark, a technology hub in Sedgefield.
Magnitude Biosciences, a spinout from Durham University, uses the tiny nematode worm C.elegans coupled with their unique imaging technology to offer research services in the fields of ageing, neurodegenerative diseases like Alzheimer’s and research into how gut bacteria affect health. Their services can speed up drug discovery for pharma and biotech
companies.
Magnitude Biosciences Chief Executive David Weinkove commented: “Our automated methods allow us to run many experiments remotely. This investment allows us to work at full speed while staying COVID-safe in our new lab at NETPark, Sedgefield. We are really happy to employ new people at this difficult time for the local economy.’’
Picture: Dr Sushmita Maitra, new member of the Magnitude Biosciences team who started work this month.
Sean Nicolson from Saker Capital added: “Since its formation Magnitude has expanded the range of services offered and now supports drug discovery in the anti-ageing and neurodegenerative disease fields as well as environmental toxicity testing. Magnitude’s technology provides rich insights into drug efficacy and mode of action.”
Alex Buchan from Northstar Ventures Capital concurred: ‘’Magnitude has demonstrated high agility and resilience during the pandemic and has proven to be a fast growing business in trying times. Our investment will consolidate its position as a rising contract research services provider to the UK’s biotech sector.’’
Dr Tim Hammond, Director of Commercialisation and Economic Development at Durham University, and Project Lead for Northern Accelerator, concluded: “We’ve supported Magnitude Biosciences from a seed of an idea in an innovative academic’s mind, through to the formation of a promising company and their recent move to a new base at NETPark. It’s fantastic to hear they have secured government funding to grow their workforce and capabilities during a challenging time when many labs are running at reduced capacity.“
Press Contact
Dr Frederique Tholozan, Business Development Lead Magnitude Biosciences Ltd
Email: fred@magnitudebiosciences.com
Editor’s notes:
- Magnitude Biosciences is a Durham University spin-out founded in 2018 from the joint efforts of Dr. David Weinkove (Biosciences) and Dr. Christopher Saunter (Physics).
- Magnitude Biosciences technology platform uses invertebrates (nematode worms) as a time and cost-efficient alternative to mouse studies for early preclinical drug development and fundamental academic research.
- Magnitude Biosciences technology is available as contract research services for the fields of ageing, age-related diseases, host-microbiome interactions and toxicity testing.
- More information is available on www.magnitudebiosciences.com
- The Future Fund is an initiative from the UK government to support innovative businesses in the UK during the Covid-19 pandemic.
- More information is available on https://www.gov.uk/guidance/future-fund
- Northstar Ventures is one of the leading early stage investors in UK businesses, and actively mentor the companies they support, as well as providing financial backing.
- More information is available on https://www.northstarventures.co.uk/
- Saker Capital is a specialty real estate investment and advisory firm, leveraging speed, agility, knowledge, experience and global reach to meet their clients’ strategic objectives
- More information is available on https://sakercapital.com/
To find out how Magnitude Biosciences can support your research contact us via info@magnitudebiosciences.com
Press Contact:
Jessica Evans jess@magnitudebiosciences.com
Related Press Releases
Magnitude Biosciences: Revolutionising Research
Contract research organisation Magnitude Biosciences is projecting significant growth as it looks to...
Read More
Life Sciences consortium celebrate collective multi-million Biomedical Catalyst 2023 Innovate UK grant
Press Release: 24th July 2023 Photo: From left to right: Prof Carrie Ambler, (LightOx) Dr Sam Whit...
Read More
Magnitude Biosciences awarded grant to accelerate the identification of compounds that could slow ageing or treat age-related diseases
Photo: The Magnitude Biosciences Team May 2023, Sedgefield, United Kingdom Magnitude Biosciences Lim...
Read More
Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services
Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevit...
Read More
Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth
North East UK Biotech Magnitude Biosciences announces new CEO, Fozia Saleem, to accelerate the growt...
Read More
SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics
Biotech entrepreneur Ethan Perlstein works with Magnitude Biosciences to reveal a new target for age...
Read More
Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing
The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing res...
Read More
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms
The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims ...
Read More
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand
Durham, UK – July 29, 2021 Magnitude Biosciences, the world’s leading commercial lab service...
Read More
Magnitude Biosciences secures its second round of funding to support its pre-clinical research services
Magnitude Biosciences secures its second round of funding to support its pre-clinical research servi...
Read More
Magnitude Biosciences announces new hires to support continued growth
Durham, UK – March 2021 Magnitude Biosciences, a spin-out from Durham University and the leadi...
Read More
Magnitude Biosciences secures UK government Future Fund to expand its workforce.
Durham, UK – August 2020 Research into new medicines is needed more than ever, but research la...
Read More
Magnitude Biosciences’ new COVID-19 compatible laboratory is fully operational and we are ready to support your research
Magnitude Biosciences moves its unique COVID-19 compatibletechnology to a new lab at NETPark in Sedg...
Read More
Get regular updates in your inbox
Sign up to our newsletter today, to get access to the latest company and industry news
